Patents by Inventor Gregory J. LaRosa

Gregory J. LaRosa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CCR2 antibodies and methods of use therefor
    Publication number: 20040265303
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: April 16, 2004
    Publication date: December 30, 2004
    Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporation
    Inventors: Gregory J. LaRosa, Walter Newman
  • Humanized anti-CCR2 antibodies and methods of use therefor
    Publication number: 20040132980
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: January 27, 2004
    Publication date: July 8, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Imidazolidine compounds
    Publication number: 20040127507
    Abstract: Disclosed are novel compounds and a method of treating inflammatory diseases.
    Type: Application
    Filed: December 9, 2003
    Publication date: July 1, 2004
    Applicants: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Jay R. Luly, Gregory J. LaRosa
  • Humanized anti-CCR2 antibodies and methods of use therefor
    Publication number: 20040126851
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: January 27, 2004
    Publication date: July 1, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Imidazolidine compounds
    Publication number: 20040122026
    Abstract: Disclosed are novel compounds and a method of treating inflammatory diseases.
    Type: Application
    Filed: December 9, 2003
    Publication date: June 24, 2004
    Applicants: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Jay R. Luly, Gregory J. LaRosa
  • Recombinant anti-CCR2 antibodies and methods of use therefor
    Patent number: 6727349
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: April 27, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Humanized anti-CCR2 antibodies and methods of use therefor
    Patent number: 6696550
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: February 24, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Imidazolidine compounds
    Publication number: 20030225288
    Abstract: Disclosed are novel compounds and a method of treating inflammatory diseases.
    Type: Application
    Filed: April 12, 2002
    Publication date: December 4, 2003
    Applicants: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Jay R. Luly, Gregory J. LaRosa
  • Anti-CCR2 antibodies and methods of use therefor
    Publication number: 20030165494
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: July 3, 2001
    Publication date: September 4, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Walter Newman
  • Imidazolidine compounds
    Patent number: 6495569
    Abstract: Disclosed are novel compounds and a method of treating inflammatory diseases. The method comprises administering to an individual in need an effective amount of an imidazolidine compound represented by Structural Formula (I): and physiologically or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: December 17, 2002
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Rie Komatsu, Gregory J. LaRosa, Jay R. Luly
  • Anti-CCR2 antibodies and methods of use therefor
    Patent number: 6491915
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: December 10, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Imidazolidine compounds
    Patent number: 6469002
    Abstract: Disclosed are novel compounds and a method of treating inflammatory diseases. The method comprises administering to an individual in need an effective amount of an imidazolidine compound represented by Structural Formula (I): and physiologically or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: October 22, 2002
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Rie Komatsu, Gregory J. LaRosa, Jay R. Luly
  • Humanized anti-CCR2 antibodies and methods of use therefor
    Publication number: 20020150576
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: April 23, 2001
    Publication date: October 17, 2002
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Anti-CCR2 antibodies and methods of use therefor
    Publication number: 20020150570
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: June 29, 2001
    Publication date: October 17, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Anti-CCR2 antibodies and methods of use therefor
    Patent number: 6458353
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: October 1, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Anti-CCR2 antibodies and methods of use therefor
    Patent number: 6451522
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: September 17, 2002
    Assignee: Millennium Pharmacueticals, Inc.
    Inventor: Gregory J. LaRosa
  • Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies
    Patent number: 6448021
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: September 10, 2002
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Anti-CCR2 antibodies
    Patent number: 6406694
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: June 18, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies
    Patent number: 6406865
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: June 18, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Method of inhibiting leukocyte trafficking by anti-CCR2 amino-terminal domain antibodies
    Patent number: 6395497
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: May 28, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa